AnnotSV ID	SV chrom	SV start	SV end	SV length	SV type	ID	REF	ALT	QUAL	FILTER	INFO	FORMAT	NA12878_HG001	AnnotSV type	Gene name	NM	CDS length	tx length	location	location2	intersectStart	intersectEnd	DGV_GAIN_IDs	DGV_GAIN_n_samples_with_SV	DGV_GAIN_n_samples_tested	DGV_GAIN_Frequency	DGV_LOSS_IDs	DGV_LOSS_n_samples_with_SV	DGV_LOSS_n_samples_tested	DGV_LOSS_Frequency	GD_ID	GD_AN	GD_N_HET	GD_N_HOMALT	GD_AF	GD_POPMAX_AF	GD_ID_others	1000g_event	1000g_AF	1000g_max_AF	IMH_ID	IMH_AF	IMH_ID_others	promoters	dbVar_event	dbVar_variant	dbVar_status	TADcoordinates	ENCODEexperiments	GCcontent_left	GCcontent_right	Repeats_coord_left	Repeats_type_left	Repeats_coord_right	Repeats_type_right	ACMG	Phenotypes	Inheritance	morbidGenesCandidates	Mim Number	morbidGenes	HI_CGscore	TriS_CGscore	DDD_status	DDD_mode	DDD_consequence	DDD_disease	DDD_pmids	HI_DDDpercent	synZ_ExAC	misZ_ExAC	pLI_ExAC	delZ_ExAC	dupZ_ExAC	cnvZ_ExAC	AnnotSV ranking
12_50505001_50505022_<STR16>_1	12	50505001	50505022		<STR16>	.	T	<STR16>	.	PASS	END=50505022;REF=7;RL=21;RU=GGC;VARID=DIP2B;REPID=DIP2B	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:7/16:7-7/16-16:12/13:8/10:0/0:26.850972	full	DIP2B									0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_INV_12_600		-1	-1		-1	12:11348553-95637272_INV;12:30757997-51226316_INV;12:40539484-113039119_INV;12:47213125-71357208_INV							0.735	0.740	12:50505001-50505053	(GGC)n	12:50505001-50505053	(GGC)n					611379	yes								27.8	-0.342715073991275	2.94498922134151	0.999994399403232	1.49877452958391	1.74259227422189	1.85937346161046	2
12_50505001_50505022_<STR16>_1	12	50505001	50505022		<STR16>	.	T	<STR16>	.	PASS	END=50505022;REF=7;RL=21;RU=GGC;VARID=DIP2B;REPID=DIP2B	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:7/16:7-7/16-16:12/13:8/10:0/0:26.850972	split	DIP2B	NM_173602	0	22	exon1-exon1	5'UTR	50505001	50505022		0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_INV_12_600		-1	-1		-1	12:11348553-95637272_INV;12:30757997-51226316_INV;12:40539484-113039119_INV;12:47213125-71357208_INV														Mental retardation, FRA12A type, 136630 (3)	AD		611379	yes			possible	monoallelic	cis-regulatory or promotor mutation	MENTAL RETARDATION, FRA12A TYPE	17236128	27.8	-0.342715073991275	2.94498922134151	0.999994399403232	1.49877452958391	1.74259227422189	1.85937346161046	2
13_70139353_70139383_<STR13>_1	13	70139353	70139383		<STR13>	.	A	<STR13>	.	PASS	END=70139383;REF=10;RL=30;RU=CTA;VARID=ATXN8OS_CTA;REPID=ATXN8OS_CTA	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/1:SPANNING/SPANNING:13/13:13-13/13-13:13/13:11/11:0/0:28.289417	full	ATXN8OS									0	0	-1		0	0	-1					-1	-1			-1	-1		-1	13:69999065-71028663_DUP;13:67378459-71217205_DEL;13:70079279-70219612_DEL;13:32383136-100111306_INV;13:42622758-110043479_INV;13:55150890-76780371_INV;13:63639789-112722346_INV;13:69697530-72987495_INV							0.455	0.400	13:70139351-70139383/13:70139383-70139429	(TAC)n/(CTG)n	13:70139351-70139383/13:70139383-70139429	(TAC)n/(CTG)n				yes	603680	yes															4
13_70139353_70139383_<STR13>_1	13	70139353	70139383		<STR13>	.	A	<STR13>	.	PASS	END=70139383;REF=10;RL=30;RU=CTA;VARID=ATXN8OS_CTA;REPID=ATXN8OS_CTA	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/1:SPANNING/SPANNING:13/13:13-13/13-13:13/13:11/11:0/0:28.289417	split	ATXN8OS	NR_002717	0	31	exon5-exon5	UTR	70139353	70139383		0	0	-1		0	0	-1					-1	-1			-1	-1		-1	13:69999065-71028663_DUP;13:67378459-71217205_DEL;13:70079279-70219612_DEL;13:32383136-100111306_INV;13:42622758-110043479_INV;13:55150890-76780371_INV;13:63639789-112722346_INV;13:69697530-72987495_INV														Spinocerebellar ataxia 8, 608768 (3)/ (Parkinson disease, susceptibility to), 168600 (3)	AD/AD, Multifactorial	yes	603680	yes															4
13_70139383_70139428_<STR16>_1	13	70139383	70139428		<STR16>	.	A	<STR16>	.	PASS	END=70139428;REF=15;RL=45;RU=CTG;VARID=ATXN8OS;REPID=ATXN8OS	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:15/16:15-15/16-16:6/5:8/8:0/0:28.289417	full	ATXN8OS									0	0	-1		0	0	-1					-1	-1			-1	-1		-1	13:69999065-71028663_DUP;13:67378459-71217205_DEL;13:70079279-70219612_DEL;13:32383136-100111306_INV;13:42622758-110043479_INV;13:55150890-76780371_INV;13:63639789-112722346_INV;13:69697530-72987495_INV							0.400	0.345	13:70139351-70139383/13:70139383-70139429	(TAC)n/(CTG)n	13:70139351-70139383/13:70139383-70139429	(TAC)n/(CTG)n				yes	603680	yes															4
13_70139383_70139428_<STR16>_1	13	70139383	70139428		<STR16>	.	A	<STR16>	.	PASS	END=70139428;REF=15;RL=45;RU=CTG;VARID=ATXN8OS;REPID=ATXN8OS	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:15/16:15-15/16-16:6/5:8/8:0/0:28.289417	split	ATXN8OS	NR_002717	0	46	exon5-exon5	UTR	70139383	70139428		0	0	-1		0	0	-1					-1	-1			-1	-1		-1	13:69999065-71028663_DUP;13:67378459-71217205_DEL;13:70079279-70219612_DEL;13:32383136-100111306_INV;13:42622758-110043479_INV;13:55150890-76780371_INV;13:63639789-112722346_INV;13:69697530-72987495_INV														Spinocerebellar ataxia 8, 608768 (3)/ (Parkinson disease, susceptibility to), 168600 (3)	AD/AD, Multifactorial	yes	603680	yes															4
14_92071009_92071042_<STR20>,<STR21>_1	14	92071009	92071042		<STR20>,<STR21>	.	C	<STR20>,<STR21>	.	PASS	END=92071042;REF=11;RL=33;RU=GCT;VARID=ATXN3;REPID=ATXN3	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:20/21:20-20/21-21:8/5:17/17:0/0:28.848812	full	ATXN3									0	0	-1		0	0	-1					-1	-1			-1	-1		-1	14:91569491-92338408_DUP;14:23629192-97505158_INV							0.445	0.415	14:92071010-92071052	(CTG)n	14:92071010-92071052	(CTG)n					607047	yes								9.03	0.309150553063112	0.806176274028153	0.102433293100603	1.0835899357099	-0.225677633839447	0.2560504644898	2
14_92071009_92071042_<STR20>,<STR21>_1	14	92071009	92071042		<STR20>,<STR21>	.	C	<STR20>,<STR21>	.	PASS	END=92071042;REF=11;RL=33;RU=GCT;VARID=ATXN3;REPID=ATXN3	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:20/21:20-20/21-21:8/5:17/17:0/0:28.848812	split	ATXN3	NM_001127696	34	34	exon9-exon9	CDS	92071009	92071042		0	0	-1		0	0	-1					-1	-1			-1	-1		-1	14:91569491-92338408_DUP;14:23629192-97505158_INV														Machado-Joseph disease, 109150 (3)	AD		607047	yes								9.03	0.309150553063112	0.806176274028153	0.102433293100603	1.0835899357099	-0.225677633839447	0.2560504644898	2
16_87604287_87604329_<STR16>_1	16	87604287	87604329		<STR16>	.	C	<STR16>	.	PASS	END=87604329;REF=14;RL=42;RU=CTG;VARID=JPH3;REPID=JPH3	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:14/16:14-14/16-16:13/11:15/16:0/0:26.371490	full	JPH3									0	0	-1		0	0	-1					-1	-1			-1	-1		-1	16:29226963-88193867_INV							0.605	0.630	16:87604282-87604329	(GCT)n	16:87604282-87604329	(GCT)n					605268	yes								33.27	-0.289523673349551	1.27589782238618	0.98051841096401	0.216965522472953	-1.0762112530597	-0.765482067324543	2
16_87604287_87604329_<STR16>_1	16	87604287	87604329		<STR16>	.	C	<STR16>	.	PASS	END=87604329;REF=14;RL=42;RU=CTG;VARID=JPH3;REPID=JPH3	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:14/16:14-14/16-16:13/11:15/16:0/0:26.371490	split	JPH3	NM_001271604	43	43	exon2-exon2	CDS	87604287	87604329		0	0	-1		0	0	-1					-1	-1			-1	-1		-1	16:29226963-88193867_INV														Huntington disease-like 2, 606438 (3)	AD		605268	yes								33.27	-0.289523673349551	1.27589782238618	0.98051841096401	0.216965522472953	-1.0762112530597	-0.765482067324543	2
18_55586155_55586227_<STR17>,<STR27>_1	18	55586155	55586227		<STR17>,<STR27>	.	G	<STR17>,<STR27>	.	PASS	END=55586227;REF=24;RL=72;RU=CAG;VARID=TCF4;REPID=TCF4	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:17/27:17-17/27-27:4/6:12/14:0/0:20.617711	full	TCF4									0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DEL_18_166771;gnomAD-SV_v2.1_INV_18_763		-1	-1		-1								0.585	0.515	18:55586113-55586153/18:55586153-55586229	(GAG)n/(AGC)n	18:55586113-55586153/18:55586153-55586229	(GAG)n/(AGC)n				yes	602228;602272	yes	3							0.38	0.115006056248647	4.45337179274477	0.99961761213725	1.47734795336459	0.574828836787397	1.03093023316889	4
18_55586155_55586227_<STR17>,<STR27>_1	18	55586155	55586227		<STR17>,<STR27>	.	G	<STR17>,<STR27>	.	PASS	END=55586227;REF=24;RL=72;RU=CAG;VARID=TCF4;REPID=TCF4	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:17/27:17-17/27-27:4/6:12/14:0/0:20.617711	split	TCF4	NM_001083962	0	73	intron2-intron2	CDS	55586155	55586227		0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DEL_18_166771;gnomAD-SV_v2.1_INV_18_763		-1	-1		-1															(Diabetes mellitus, type 2, susceptibility to), 125853 (3);Corneal dystrophy, Fuchs endothelial, 3, 613267 (3)/ Pitt-Hopkins syndrome, 610954 (3)	AD;AD	yes	602228;602272	yes	3	0	confirmed	monoallelic	loss of function	PITT-HOPKINS SYNDROME	18728071;17436255;17436254	0.38	0.115006056248647	4.45337179274477	0.99961761213725	1.47734795336459	0.574828836787397	1.03093023316889	4
19_13207858_13207897_<STR11>,<STR12>_1	19	13207858	13207897		<STR11>,<STR12>	.	C	<STR11>,<STR12>	.	PASS	END=13207897;REF=13;RL=39;RU=CTG;VARID=CACNA1A;REPID=CACNA1A	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:11/12:11-11/12-12:5/4:11/12:0/0:14.384449	full	CACNA1A									0	0	-1		0	0	-1					-1	-1			-1	-1		-1	19:1692675-41507766_INV;19:10757659-54182157_INV;19:11963564-20150888_INV;19:12342310-19691845_INV							0.770	0.775	19:13207858-13207898	(CTG)n	19:13207858-13207898	(CTG)n					601011	yes	3							35.52	1.18148330722263	7.24830614237983	0.999999999843422	1.41338495639277	1.65083645536139	1.86751979318996	2
19_13207858_13207897_<STR11>,<STR12>_1	19	13207858	13207897		<STR11>,<STR12>	.	C	<STR11>,<STR12>	.	PASS	END=13207897;REF=13;RL=39;RU=CTG;VARID=CACNA1A;REPID=CACNA1A	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:11/12:11-11/12-12:5/4:11/12:0/0:14.384449	split	CACNA1A	NM_001127222	40	40	exon47-exon47	CDS	13207858	13207897		0	0	-1		0	0	-1					-1	-1			-1	-1		-1	19:1692675-41507766_INV;19:10757659-54182157_INV;19:11963564-20150888_INV;19:12342310-19691845_INV														Spinocerebellar ataxia 6, 183086 (3)/ Epileptic encephalopathy, early infantile, 42, 617106 (3)/ Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3)/ Episodic ataxia, type 2, 108500 (3)/ Migraine, familial hemiplegic, 1, 141500 (3)	AD		601011	yes	3	0	probable	monoallelic	all missense/in frame	EPILEPTIC ENCEPHALOPATHY	28927557;28742085;29366381;27476654;23934111	35.52	1.18148330722263	7.24830614237983	0.999999999843422	1.41338495639277	1.65083645536139	1.86751979318996	2
19_45770204_45770264_<STR5>,<STR13>_1	19	45770204	45770264		<STR5>,<STR13>	.	C	<STR5>,<STR13>	.	PASS	END=45770264;REF=20;RL=60;RU=CAG;VARID=DMPK;REPID=DMPK	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:5/13:5-5/13-13:8/7:4/7:0/0:21.896328	full	DM1-AS/DMPK									0	0	-1	gssvL58871	2	863	0.00231750					-1	-1			-1	-1		-1	19:10757659-54182157_INV							0.650	0.690	19:45770204-45770266/19:45770290-45770333	(CAG)n/(GCCCCG)n	19:45770204-45770266/19:45770290-45770333	(CAG)n/(GCCCCG)n					605377	yes								49.83	0.425893209308494	1.39938895128029	0.333105828885844	0.129585563803887	1.01867790101199	0.821144234301687	2
19_45770204_45770264_<STR5>,<STR13>_1	19	45770204	45770264		<STR5>,<STR13>	.	C	<STR5>,<STR13>	.	PASS	END=45770264;REF=20;RL=60;RU=CAG;VARID=DMPK;REPID=DMPK	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:5/13:5-5/13-13:8/7:4/7:0/0:21.896328	split	DM1-AS	NR_147193	0	61	intron1-intron1	UTR	45770204	45770264		0	0	-1	gssvL58871	2	863	0.00231750					-1	-1			-1	-1		-1	19:10757659-54182157_INV																																	2
19_45770204_45770264_<STR5>,<STR13>_1	19	45770204	45770264		<STR5>,<STR13>	.	C	<STR5>,<STR13>	.	PASS	END=45770264;REF=20;RL=60;RU=CAG;VARID=DMPK;REPID=DMPK	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:5/13:5-5/13-13:8/7:4/7:0/0:21.896328	split	DMPK	NM_001288765	0	61	exon13-exon13	3'UTR	45770204	45770264		0	0	-1	gssvL58871	2	863	0.00231750					-1	-1			-1	-1		-1	19:10757659-54182157_INV														Myotonic dystrophy 1, 160900 (3)	AD		605377	yes			confirmed	monoallelic	dominant negative	DYSTROPHIA MYOTONICA TYPE 1		49.83	0.425893209308494	1.39938895128029	0.333105828885844	0.129585563803887	1.01867790101199	0.821144234301687	2
20_2652757_2652775_<STR2>_1	20	2652757	2652775		<STR2>	.	G	<STR2>	.	PASS	END=2652775;REF=3;RL=18;RU=CGCCTG;VARID=NOP56_CGCCTG;REPID=NOP56_CGCCTG	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:3/2:3-3/2-2:12/11:0/0:0/0:27.650108	full	NOP56								gssvG22574	4	12365	0.00032349		0	0	-1					-1	-1	gnomAD-SV_v2.1_INV_20_800		-1	-1		-1	20:2055842-2737425_DUP;20:2603179-2656572_DUP							0.740	0.740	20:2652732-2652775	(GGGCCT)n	20:2652732-2652775	(GGGCCT)n					614154	yes								12.69	-0.284200528512332	0.733534691836002	0.94199624123066	0.509077577853254	0.0536939006979634	0.261155305737806	2
20_2652757_2652775_<STR2>_1	20	2652757	2652775		<STR2>	.	G	<STR2>	.	PASS	END=2652775;REF=3;RL=18;RU=CGCCTG;VARID=NOP56_CGCCTG;REPID=NOP56_CGCCTG	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:3/2:3-3/2-2:12/11:0/0:0/0:27.650108	split	NOP56	NM_006392	0	19	intron1-intron1	CDS	2652757	2652775	gssvG22574	4	12365	0.00032349		0	0	-1					-1	-1	gnomAD-SV_v2.1_INV_20_800		-1	-1		-1	20:2055842-2737425_DUP;20:2603179-2656572_DUP														Spinocerebellar ataxia 36, 614153 (3)	AD		614154	yes								12.69	-0.284200528512332	0.733534691836002	0.94199624123066	0.509077577853254	0.0536939006979634	0.261155305737806	2
21_43776443_43776479_<STR2>_1	21	43776443	43776479		<STR2>	.	G	<STR2>	.	PASS	END=43776479;REF=3;RL=36;RU=CGCGGGGCGGGG;VARID=CSTB;REPID=CSTB	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:3/2:3-3/2-2:5/5:10/10:0/0:24.133909	full										0	0	-1		0	0	-1					-1	-1			-1	-1		-1								0.785	0.785	21:43776444-43776479	G-rich	21:43776444-43776479	G-rich																					2
22_45795354_45795424_<STR13>,<STR16>_1	22	45795354	45795424		<STR13>,<STR16>	.	G	<STR13>,<STR16>	.	PASS	END=45795424;REF=14;RL=70;RU=ATTCT;VARID=ATXN10;REPID=ATXN10	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:13/16:13-13/16-16:5/5:24/26:0/0:30.606911	full	ATXN10									0	0	-1		0	0	-1					-1	-1			-1	-1		-1	22:45540805-45871649_DUP;22:44479418-47655346_INV;22:45618166-47591502_INV							0.265	0.380	22:45794597-45795343/22:45795354-45795424/22:45795424-45795572	L1ME1/(ATTCT)n/AluSx1	22:45794597-45795343/22:45795354-45795424/22:45795424-45795572	L1ME1/(ATTCT)n/AluSx1					611150	yes								78.38	0.110910978806873	-1.28470259574575	0.624541711334306	0.874818832435991	1.10534962506054	1.30981496518558	2
22_45795354_45795424_<STR13>,<STR16>_1	22	45795354	45795424		<STR13>,<STR16>	.	G	<STR13>,<STR16>	.	PASS	END=45795424;REF=14;RL=70;RU=ATTCT;VARID=ATXN10;REPID=ATXN10	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:13/16:13-13/16-16:5/5:24/26:0/0:30.606911	split	ATXN10	NM_001167621	0	71	intron8-intron8	CDS	45795354	45795424		0	0	-1		0	0	-1					-1	-1			-1	-1		-1	22:45540805-45871649_DUP;22:44479418-47655346_INV;22:45618166-47591502_INV														Spinocerebellar ataxia 10, 603516 (3)	AD		611150	yes								78.38	0.110910978806873	-1.28470259574575	0.624541711334306	0.874818832435991	1.10534962506054	1.30981496518558	2
3_63912684_63912714_<STR12>_1	3	63912684	63912714		<STR12>	.	G	<STR12>	.	PASS	END=63912714;REF=10;RL=30;RU=GCA;VARID=ATXN7;REPID=ATXN7	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:10/12:10-10/12-12:6/4:4/7:0/0:19.898488	full	ATXN7									0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_INV_3_143		-1	-1		-1	3:3432406-77775308_INV;3:30036453-134858252_INV;3:31013485-130283626_INV;3:38585613-149444404_INV							0.795	0.835	3:63912684-63912716	(GCA)n	3:63912684-63912716	(GCA)n					607640	yes								17.72	0.85336181383742	0.386394557252369	0.865388523597776	0.730304227093642	0.636006512326363	0.862222958307612	2
3_63912684_63912714_<STR12>_1	3	63912684	63912714		<STR12>	.	G	<STR12>	.	PASS	END=63912714;REF=10;RL=30;RU=GCA;VARID=ATXN7;REPID=ATXN7	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:10/12:10-10/12-12:6/4:4/7:0/0:19.898488	split	ATXN7	NM_000333	31	31	exon3-exon3	CDS	63912684	63912714		0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_INV_3_143		-1	-1		-1	3:3432406-77775308_INV;3:30036453-134858252_INV;3:31013485-130283626_INV;3:38585613-149444404_INV														Spinocerebellar ataxia 7, 164500 (3)	AD		607640	yes								17.72	0.85336181383742	0.386394557252369	0.865388523597776	0.730304227093642	0.636006512326363	0.862222958307612	2
3_129172576_129172656_<STR15>_1	3	129172576	129172656		<STR15>	.	A	<STR15>	.	PASS	END=129172656;REF=20;RL=80;RU=CAGG;VARID=CNBP;REPID=CNBP	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/1:SPANNING/SPANNING:15/15:15-15/15-15:8/8:8/8:0/0:28.369330	full	CNBP									0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DEL_3_37057;gnomAD-SV_v2.1_INV_3_184		-1	-1		-1	3:30036453-134858252_INV;3:31013485-130283626_INV;3:38585613-149444404_INV;3:72502418-189537676_INV;3:75414254-130085761_INV;3:82948035-190462491_INV;3:97392263-146717868_INV;3:112595778-197475161_INV;3:125731275-130015775_INV;3:125769807-129999879_INV;3:125931291-130096656_INV							0.630	0.580	3:129172299-129172573/3:129172576-129172659/3:129172659-129172695	AluSx/(CAGG)n/(ACAG)n	3:129172299-129172573/3:129172576-129172659/3:129172659-129172695/3:129172695-129172733	AluSx/(CAGG)n/(ACAG)n/(AC)n					116955	yes								10.92	0.683528847927585	2.99129438863035	0.906630223536338	1.01216653226968	0.563475193327092	0.859240177546605	2
3_129172576_129172656_<STR15>_1	3	129172576	129172656		<STR15>	.	A	<STR15>	.	PASS	END=129172656;REF=20;RL=80;RU=CAGG;VARID=CNBP;REPID=CNBP	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/1:SPANNING/SPANNING:15/15:15-15/15-15:8/8:8/8:0/0:28.369330	split	CNBP	NM_001127192	0	81	intron1-intron1	5'UTR	129172576	129172656		0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DEL_3_37057;gnomAD-SV_v2.1_INV_3_184		-1	-1		-1	3:30036453-134858252_INV;3:31013485-130283626_INV;3:38585613-149444404_INV;3:72502418-189537676_INV;3:75414254-130085761_INV;3:82948035-190462491_INV;3:97392263-146717868_INV;3:112595778-197475161_INV;3:125731275-130015775_INV;3:125769807-129999879_INV;3:125931291-130096656_INV														Myotonic dystrophy 2, 602668 (3)	AD		116955	yes								10.92	0.683528847927585	2.99129438863035	0.906630223536338	1.01216653226968	0.563475193327092	0.859240177546605	2
3_129172656_129172696_<STR9>_1	3	129172656	129172696		<STR9>	.	G	<STR9>	.	PASS	END=129172696;REF=10;RL=40;RU=CAGA;VARID=CNBP_CAGA;REPID=CNBP_CAGA	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/1:SPANNING/SPANNING:9/9:9-9/9-9:5/5:8/8:0/0:28.369330	full	CNBP									0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DEL_3_37057;gnomAD-SV_v2.1_INV_3_184		-1	-1		-1	3:30036453-134858252_INV;3:31013485-130283626_INV;3:38585613-149444404_INV;3:72502418-189537676_INV;3:75414254-130085761_INV;3:82948035-190462491_INV;3:97392263-146717868_INV;3:112595778-197475161_INV;3:125731275-130015775_INV;3:125769807-129999879_INV;3:125931291-130096656_INV							0.580	0.525	3:129172299-129172573/3:129172576-129172659/3:129172659-129172695/3:129172695-129172733	AluSx/(CAGG)n/(ACAG)n/(AC)n	3:129172576-129172659/3:129172659-129172695/3:129172695-129172733	(CAGG)n/(ACAG)n/(AC)n					116955	yes								10.92	0.683528847927585	2.99129438863035	0.906630223536338	1.01216653226968	0.563475193327092	0.859240177546605	2
3_129172656_129172696_<STR9>_1	3	129172656	129172696		<STR9>	.	G	<STR9>	.	PASS	END=129172696;REF=10;RL=40;RU=CAGA;VARID=CNBP_CAGA;REPID=CNBP_CAGA	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/1:SPANNING/SPANNING:9/9:9-9/9-9:5/5:8/8:0/0:28.369330	split	CNBP	NM_001127192	0	41	intron1-intron1	5'UTR	129172656	129172696		0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DEL_3_37057;gnomAD-SV_v2.1_INV_3_184		-1	-1		-1	3:30036453-134858252_INV;3:31013485-130283626_INV;3:38585613-149444404_INV;3:72502418-189537676_INV;3:75414254-130085761_INV;3:82948035-190462491_INV;3:97392263-146717868_INV;3:112595778-197475161_INV;3:125731275-130015775_INV;3:125769807-129999879_INV;3:125931291-130096656_INV														Myotonic dystrophy 2, 602668 (3)	AD		116955	yes								10.92	0.683528847927585	2.99129438863035	0.906630223536338	1.01216653226968	0.563475193327092	0.859240177546605	2
3_129172696_129172732_<STR21>,<STR27>_1	3	129172696	129172732		<STR21>,<STR27>	.	A	<STR21>,<STR27>	.	PASS	END=129172732;REF=18;RL=36;RU=CA;VARID=CNBP_CA;REPID=CNBP_CA	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:21/27:21-21/27-27:2/3:11/11:0/0:28.369330	full	CNBP									0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DEL_3_37057;gnomAD-SV_v2.1_INV_3_184		-1	-1		-1	3:30036453-134858252_INV;3:31013485-130283626_INV;3:38585613-149444404_INV;3:72502418-189537676_INV;3:75414254-130085761_INV;3:82948035-190462491_INV;3:97392263-146717868_INV;3:112595778-197475161_INV;3:125731275-130015775_INV;3:125769807-129999879_INV;3:125931291-130096656_INV							0.525	0.465	3:129172576-129172659/3:129172659-129172695/3:129172695-129172733	(CAGG)n/(ACAG)n/(AC)n	3:129172576-129172659/3:129172659-129172695/3:129172695-129172733	(CAGG)n/(ACAG)n/(AC)n					116955	yes								10.92	0.683528847927585	2.99129438863035	0.906630223536338	1.01216653226968	0.563475193327092	0.859240177546605	2
3_129172696_129172732_<STR21>,<STR27>_1	3	129172696	129172732		<STR21>,<STR27>	.	A	<STR21>,<STR27>	.	PASS	END=129172732;REF=18;RL=36;RU=CA;VARID=CNBP_CA;REPID=CNBP_CA	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:21/27:21-21/27-27:2/3:11/11:0/0:28.369330	split	CNBP	NM_001127192	0	37	intron1-intron1	5'UTR	129172696	129172732		0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DEL_3_37057;gnomAD-SV_v2.1_INV_3_184		-1	-1		-1	3:30036453-134858252_INV;3:31013485-130283626_INV;3:38585613-149444404_INV;3:72502418-189537676_INV;3:75414254-130085761_INV;3:82948035-190462491_INV;3:97392263-146717868_INV;3:112595778-197475161_INV;3:125731275-130015775_INV;3:125769807-129999879_INV;3:125931291-130096656_INV														Myotonic dystrophy 2, 602668 (3)	AD		116955	yes								10.92	0.683528847927585	2.99129438863035	0.906630223536338	1.01216653226968	0.563475193327092	0.859240177546605	2
4_3074876_3074933_<STR16>,<STR18>_1	4	3074876	3074933		<STR16>,<STR18>	.	C	<STR16>,<STR18>	.	PASS	END=3074933;REF=19;RL=57;RU=CAG;VARID=HTT;REPID=HTT	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:16/18:16-16/18-18:5/4:17/19:0/0:16.781857	full	HTT									0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DUP_4_10990		-1	-1		-1	4:1330316-92330038_INV;4:2821272-17704603_INV							0.710	0.710	4:3074876-3074940/4:3074940-3075052	(CAG)n/(CGC)n	4:3074876-3074940/4:3074940-3075052	(CAG)n/(CGC)n				yes	613004;182138	yes								7.59	-0.292338464564844	2.75557960790302	0.999999999984177	-0.672019089975884	1.20702378077388	0.455761090475751	4
4_3074876_3074933_<STR16>,<STR18>_1	4	3074876	3074933		<STR16>,<STR18>	.	C	<STR16>,<STR18>	.	PASS	END=3074933;REF=19;RL=57;RU=CAG;VARID=HTT;REPID=HTT	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:16/18:16-16/18-18:5/4:17/19:0/0:16.781857	split	HTT	NM_002111	58	58	exon1-exon1	CDS	3074876	3074933		0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DUP_4_10990		-1	-1		-1	4:1330316-92330038_INV;4:2821272-17704603_INV														Huntington disease, 143100 (3)/ Lopes-Maciel-Rodan syndrome, 617435 (3);(Anxiety-related personality traits), 607834 (3)/ (Obsessive-compulsive disorder), 164230 (3)	AD/AR;/AD	yes	613004;182138	yes								7.59	-0.292338464564844	2.75557960790302	0.999999999984177	-0.672019089975884	1.20702378077388	0.455761090475751	4
4_3074939_3074966_<STR12>_1	4	3074939	3074966		<STR12>	.	G	<STR12>	.	PASS	END=3074966;REF=9;RL=27;RU=CCG;VARID=HTT_CCG;REPID=HTT_CCG	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:9/12:9-9/12-12:4/8:8/8:0/0:16.781857	full	HTT									0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DUP_4_10990		-1	-1		-1	4:1330316-92330038_INV;4:2821272-17704603_INV							0.720	0.770	4:3074876-3074940/4:3074940-3075052	(CAG)n/(CGC)n	4:3074876-3074940/4:3074940-3075052	(CAG)n/(CGC)n				yes	613004;182138	yes								7.59	-0.292338464564844	2.75557960790302	0.999999999984177	-0.672019089975884	1.20702378077388	0.455761090475751	4
4_3074939_3074966_<STR12>_1	4	3074939	3074966		<STR12>	.	G	<STR12>	.	PASS	END=3074966;REF=9;RL=27;RU=CCG;VARID=HTT_CCG;REPID=HTT_CCG	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:9/12:9-9/12-12:4/8:8/8:0/0:16.781857	split	HTT	NM_002111	28	28	exon1-exon1	CDS	3074939	3074966		0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DUP_4_10990		-1	-1		-1	4:1330316-92330038_INV;4:2821272-17704603_INV														Huntington disease, 143100 (3)/ Lopes-Maciel-Rodan syndrome, 617435 (3);(Anxiety-related personality traits), 607834 (3)/ (Obsessive-compulsive disorder), 164230 (3)	AD/AR;/AD	yes	613004;182138	yes								7.59	-0.292338464564844	2.75557960790302	0.999999999984177	-0.672019089975884	1.20702378077388	0.455761090475751	4
4_41745972_41746032_<STR36>_1	4	41745972	41746032		<STR36>	.	A	<STR36>	.	PASS	END=41746032;REF=20;RL=60;RU=GCN;VARID=PHOX2B;REPID=PHOX2B	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/FLANKING:20/36:20-20/20-36:5/0:16/17:0/0:21.736501	full	PHOX2B									0	0	-1		0	0	-1					-1	-1			-1	-1		-1	4:1330316-92330038_INV;4:4772331-76608755_INV;4:9660215-57055288_INV;4:10537451-136423901_INV;4:21291889-139485605_INV;4:21757281-83521389_INV;4:24547861-125073959_INV;4:30348256-115788825_INV;4:32217846-78249129_INV;4:35256165-68206148_INV;4:41369890-94869199_INV							0.810	0.845	4:41745975-41746022	(GCC)n	4:41745975-41746022	(GCC)n				yes	603851	yes								39.01	2.47385640317078	3.90161164728068	0.837006667322481	0.19045863354798	0.622431076047283	0.662858626732993	4
4_41745972_41746032_<STR36>_1	4	41745972	41746032		<STR36>	.	A	<STR36>	.	PASS	END=41746032;REF=20;RL=60;RU=GCN;VARID=PHOX2B;REPID=PHOX2B	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/FLANKING:20/36:20-20/20-36:5/0:16/17:0/0:21.736501	split	PHOX2B	NM_003924	61	61	exon3-exon3	CDS	41745972	41746032		0	0	-1		0	0	-1					-1	-1			-1	-1		-1	4:1330316-92330038_INV;4:4772331-76608755_INV;4:9660215-57055288_INV;4:10537451-136423901_INV;4:21291889-139485605_INV;4:21757281-83521389_INV;4:24547861-125073959_INV;4:30348256-115788825_INV;4:32217846-78249129_INV;4:35256165-68206148_INV;4:41369890-94869199_INV														Neuroblastoma with Hirschsprung disease, 613013 (3)/ Central hypoventilation syndrome, congenital, with or without Hirschsprung disease, 209880 (3)/ (Neuroblastoma, susceptibility to, 2), 613013 (3)	/AD/	yes	603851	yes			confirmed/confirmed	monoallelic/monoallelic	uncertain/uncertain	CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE/NEUROBLASTOMA WITH HIRSCHSPRUNG DISEASE	12640453/12438263;16691592;15024693	39.01	2.47385640317078	3.90161164728068	0.837006667322481	0.19045863354798	0.622431076047283	0.662858626732993	4
5_146878727_146878757_<STR14>_1	5	146878727	146878757		<STR14>	.	A	<STR14>	.	PASS	END=146878757;REF=10;RL=30;RU=GCT;VARID=PPP2R2B;REPID=PPP2R2B	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:10/14:10-10/14-14:4/8:13/13:0/0:21.177106	full	PPP2R2B									0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_INV_5_294		-1	-1		-1	5:93957547-155223079_DEL;5:54493873-172627819_INV;5:85192777-162907706_INV;5:96855634-159536527_INV;5:119173671-148177697_INV;5:144180364-178697960_INV							0.715	0.700	5:146878727-146878759	(GCT)n	5:146878727-146878759	(GCT)n					604325	yes								2.17	0.158971620113834	2.42006888346672	0.846109909940188				2
5_146878727_146878757_<STR14>_1	5	146878727	146878757		<STR14>	.	A	<STR14>	.	PASS	END=146878757;REF=10;RL=30;RU=GCT;VARID=PPP2R2B;REPID=PPP2R2B	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:10/14:10-10/14-14:4/8:13/13:0/0:21.177106	split	PPP2R2B	NM_181675	31	31	exon1-exon1	CDS	146878727	146878757		0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_INV_5_294		-1	-1		-1	5:93957547-155223079_DEL;5:54493873-172627819_INV;5:85192777-162907706_INV;5:96855634-159536527_INV;5:119173671-148177697_INV;5:144180364-178697960_INV														Spinocerebellar ataxia 12, 604326 (3)	AD		604325	yes								2.17	0.158971620113834	2.42006888346672	0.846109909940188				2
6_16327633_16327723_<STR31>_1	6	16327633	16327723		<STR31>	.	G	<STR31>	.	PASS	END=16327723;REF=30;RL=90;RU=TGC;VARID=ATXN1;REPID=ATXN1	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:30/31:30-30/31-31:3/5:28/28:0/0:22.535637	full	ATXN1									0	0	-1		0	0	-1					-1	-1			-1	-1		-1								0.655	0.650	6:16327633-16327724	(TGC)n	6:16327633-16327724	(TGC)n					601556	yes								5.05	-0.22262436652196	2.48613742062414	0.707344997177833				2
6_16327633_16327723_<STR31>_1	6	16327633	16327723		<STR31>	.	G	<STR31>	.	PASS	END=16327723;REF=30;RL=90;RU=TGC;VARID=ATXN1;REPID=ATXN1	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	0/1:SPANNING/SPANNING:30/31:30-30/31-31:3/5:28/28:0/0:22.535637	split	ATXN1	NM_000332	91	91	exon8-exon8	CDS	16327633	16327723		0	0	-1		0	0	-1					-1	-1			-1	-1		-1															Spinocerebellar ataxia 1, 164400 (3)	AD		601556	yes								5.05	-0.22262436652196	2.48613742062414	0.707344997177833				2
6_170561906_170562017_<STR38>_1	6	170561906	170562017		<STR38>	.	G	<STR38>	.	PASS	END=170562017;REF=37;RL=111;RU=GCA;VARID=TBP;REPID=TBP	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/1:SPANNING/SPANNING:38/38:38-38/38-38:4/4:28/28:0/0:23.574514	full	TBP								gssvG33648	3	13760	0.00021802		0	0	-1					-1	-1		DUP	0.00019968	0.001		-1								0.530	0.610	6:170561906-170562017	(GCA)n	6:170561906-170562017	(GCA)n				yes	600075	yes								6.48	-0.408801818931715	2.20111482259452	0.385613633909942	0.00919528286791156	-2.27838813328863	-1.7440270009601	4
6_170561906_170562017_<STR38>_1	6	170561906	170562017		<STR38>	.	G	<STR38>	.	PASS	END=170562017;REF=37;RL=111;RU=GCA;VARID=TBP;REPID=TBP	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/1:SPANNING/SPANNING:38/38:38-38/38-38:4/4:28/28:0/0:23.574514	split	TBP	NM_001172085	112	112	exon2-exon2	CDS	170561906	170562017	gssvG33648	3	13760	0.00021802		0	0	-1					-1	-1		DUP	0.00019968	0.001		-1															(Parkinson disease, susceptibility to), 168600 (3)/ Spinocerebellar ataxia 17, 607136 (3)	AD, Multifactorial/AD	yes	600075	yes								6.48	-0.408801818931715	2.20111482259452	0.385613633909942	0.00919528286791156	-2.27838813328863	-1.7440270009601	4
9_27573528_27573546_<STR2>,<STR5>_1	9	27573528	27573546		<STR2>,<STR5>	.	C	<STR2>,<STR5>	.	PASS	END=27573546;REF=3;RL=18;RU=GGCCCC;VARID=C9ORF72;REPID=C9ORF72	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:2/5:2-2/5-5:6/11:4/9:0/0:23.974082	full	C9orf72									0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DUP_9_26595;gnomAD-SV_v2.1_DUP_9_26612;gnomAD-SV_v2.1_DUP_9_26613;gnomAD-SV_v2.1_DUP_9_26614		-1	-1		-1								0.725	0.700	9:27573484-27573546	(GCCCCG)n	9:27573484-27573546	(GCCCCG)n					614260	yes								11.73	-1.69077452406282	0.0160477419573943	0.0111433918342946	-1.43365950702464	-0.297509028473295	-0.76830156421199	2
9_27573528_27573546_<STR2>,<STR5>_1	9	27573528	27573546		<STR2>,<STR5>	.	C	<STR2>,<STR5>	.	PASS	END=27573546;REF=3;RL=18;RU=GGCCCC;VARID=C9ORF72;REPID=C9ORF72	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:2/5:2-2/5-5:6/11:4/9:0/0:23.974082	split	C9orf72	NM_001256054	0	19	intron1-intron1	5'UTR	27573528	27573546		0	0	-1		0	0	-1					-1	-1	gnomAD-SV_v2.1_DUP_9_26595;gnomAD-SV_v2.1_DUP_9_26612;gnomAD-SV_v2.1_DUP_9_26613;gnomAD-SV_v2.1_DUP_9_26614		-1	-1		-1															Frontotemporal dementia and/or amyotrophic lateral sclerosis 1, 105550 (3)	AD		614260	yes								11.73	-1.69077452406282	0.0160477419573943	0.0111433918342946	-1.43365950702464	-0.297509028473295	-0.76830156421199	2
9_69037261_69037286_<STR27>,<STR30>_1	9	69037261	69037286		<STR27>,<STR30>	.	T	<STR27>,<STR30>	.	PASS	END=69037286;REF=25;RL=25;RU=A;VARID=FXN_A;REPID=FXN_A	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:27/30:27-27/30-30:9/2:8/10:0/0:24.853132	full	FXN								gssvG39782	3	12129	0.00024734		0	0	-1					-1	-1	gnomAD-SV_v2.1_DUP_9_27309		-1	-1		-1	9:68780682-69356270_DUP;9:68885220-69216235_DUP;9:68982680-69234470_DUP;9:69037265-69045395_DEL;9:65437054-134286391_INV							0.450	0.460	9:69037141-69037494	AluSx	9:69037141-69037494	AluSx					606829	yes								66.77	-0.104401815070801	0.813331274759873	0.803512809070651	-0.903609614373761	-1.20985855447785	-1.16534074828701	2
9_69037261_69037286_<STR27>,<STR30>_1	9	69037261	69037286		<STR27>,<STR30>	.	T	<STR27>,<STR30>	.	PASS	END=69037286;REF=25;RL=25;RU=A;VARID=FXN_A;REPID=FXN_A	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:27/30:27-27/30-30:9/2:8/10:0/0:24.853132	split	FXN	NM_000144	0	26	intron1-intron1	CDS	69037261	69037286	gssvG39782	3	12129	0.00024734		0	0	-1					-1	-1	gnomAD-SV_v2.1_DUP_9_27309		-1	-1		-1	9:68780682-69356270_DUP;9:68885220-69216235_DUP;9:68982680-69234470_DUP;9:69037265-69045395_DEL;9:65437054-134286391_INV														Friedreich ataxia with retained reflexes, 229300 (3)/ Friedreich ataxia, 229300 (3)	AR		606829	yes	30	0						66.77	-0.104401815070801	0.813331274759873	0.803512809070651	-0.903609614373761	-1.20985855447785	-1.16534074828701	2
9_69037286_69037304_<STR9>_1	9	69037286	69037304		<STR9>	.	A	<STR9>	.	PASS	END=69037304;REF=6;RL=18;RU=GAA;VARID=FXN;REPID=FXN	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/1:SPANNING/SPANNING:9/9:9-9/9-9:10/10:10/10:0/0:24.853132	full	FXN								gssvG39782	3	12129	0.00024734		0	0	-1					-1	-1	gnomAD-SV_v2.1_DUP_9_27309		-1	-1		-1	9:68780682-69356270_DUP;9:68885220-69216235_DUP;9:68982680-69234470_DUP;9:69037265-69045395_DEL;9:65437054-134286391_INV							0.460	0.475	9:69037141-69037494	AluSx	9:69037141-69037494	AluSx					606829	yes								66.77	-0.104401815070801	0.813331274759873	0.803512809070651	-0.903609614373761	-1.20985855447785	-1.16534074828701	2
9_69037286_69037304_<STR9>_1	9	69037286	69037304		<STR9>	.	A	<STR9>	.	PASS	END=69037304;REF=6;RL=18;RU=GAA;VARID=FXN;REPID=FXN	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/1:SPANNING/SPANNING:9/9:9-9/9-9:10/10:10/10:0/0:24.853132	split	FXN	NM_000144	0	19	intron1-intron1	CDS	69037286	69037304	gssvG39782	3	12129	0.00024734		0	0	-1					-1	-1	gnomAD-SV_v2.1_DUP_9_27309		-1	-1		-1	9:68780682-69356270_DUP;9:68885220-69216235_DUP;9:68982680-69234470_DUP;9:69037265-69045395_DEL;9:65437054-134286391_INV														Friedreich ataxia with retained reflexes, 229300 (3)/ Friedreich ataxia, 229300 (3)	AR		606829	yes	30	0						66.77	-0.104401815070801	0.813331274759873	0.803512809070651	-0.903609614373761	-1.20985855447785	-1.16534074828701	2
X_67545316_67545385_<STR21>,<STR25>_1	X	67545316	67545385		<STR21>,<STR25>	.	T	<STR21>,<STR25>	.	PASS	END=67545385;REF=23;RL=69;RU=GCA;VARID=AR;REPID=AR	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:21/25:21-21/25-25:7/1:20/24:0/0:17.021598	full	AR									0	0	-1		0	0	-1					-1	-1			-1	-1		-1	X:65710540-68026712_DUP;X:23472124-121561945_INV;X:65387005-68605087_INV							0.665	0.645	X:67545316-67545419	(GCA)n	X:67545316-67545419	(GCA)n				yes	313700	yes	3							0.35	-0.0209058563241717	1.57842633474417	0.992109209508219				4
X_67545316_67545385_<STR21>,<STR25>_1	X	67545316	67545385		<STR21>,<STR25>	.	T	<STR21>,<STR25>	.	PASS	END=67545385;REF=23;RL=69;RU=GCA;VARID=AR;REPID=AR	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:21/25:21-21/25-25:7/1:20/24:0/0:17.021598	split	AR	NM_000044	70	70	exon1-exon1	CDS	67545316	67545385		0	0	-1		0	0	-1					-1	-1			-1	-1		-1	X:65710540-68026712_DUP;X:23472124-121561945_INV;X:65387005-68605087_INV														Hypospadias 1, XL, 300633 (3)/ Androgen insensitivity, 300068 (3)/ (Prostate cancer, susceptibility to), 176807 (3)/ Androgen insensitivity, partial, with or without breast cancer, 312300 (3)/ Spinal and bulbar muscular atrophy of Kennedy, 313200 (3)	XLR/XLR/AD, Somatic mutation/XLR/XLR	yes	313700	yes	3	0	both RD and IF/both RD and IF	hemizygous/hemizygous	dominant negative/loss of function	SPINAL AND BULBAR MUSCULAR ATROPHY/ANDROGEN INSENSITIVITY SYNDROME		0.35	-0.0209058563241717	1.57842633474417	0.992109209508219				4
X_147912050_147912110_<STR30>,<STR31>_1	X	147912050	147912110		<STR30>,<STR31>	.	G	<STR30>,<STR31>	.	PASS	END=147912110;REF=20;RL=60;RU=CGG;VARID=FMR1;REPID=FMR1	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:30/31:30-30/31-31:2/4:24/24:0/0:20.537797	full	FMR1									0	0	-1		0	0	-1					-1	-1			-1	-1		-1	X:112310517-152275319_INV							0.875	0.820	X:147911978-147912111	(GGC)n	X:147911978-147912111	(GGC)n					309550	yes	3							2.45	0.925952363469401	3.04370283043583	0.296796463493601				2
X_147912050_147912110_<STR30>,<STR31>_1	X	147912050	147912110		<STR30>,<STR31>	.	G	<STR30>,<STR31>	.	PASS	END=147912110;REF=20;RL=60;RU=CGG;VARID=FMR1;REPID=FMR1	GT:SO:REPCN:REPCI:ADSP:ADFL:ADIR:LC	1/2:SPANNING/SPANNING:30/31:30-30/31-31:2/4:24/24:0/0:20.537797	split	FMR1	NM_001185081	0	61	exon1-exon1	5'UTR	147912050	147912110		0	0	-1		0	0	-1					-1	-1			-1	-1		-1	X:112310517-152275319_INV														Premature ovarian failure 1, 311360 (3)/ Fragile X tremor/ataxia syndrome, 300623 (3)/ Fragile X syndrome, 300624 (3)	XL/XLD/XLD		309550	yes	3	0	both RD and IF/confirmed/both RD and IF	hemizygous/hemizygous/x-linked dominant	activating/loss of function/uncertain	FRAGILE X TREMOR/ATAXIA SYNDROME/FRAGILE X SYNDROME/PREMATURE OVARIAN FAILURE SYNDROME TYPE 1		2.45	0.925952363469401	3.04370283043583	0.296796463493601				2
